Physician profile
Jillian Saad
NPI 1871814269
$961.92
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $488 · 2021: $136 · 2024: $42.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $382.70 | 2019-2020 | |
| Lundbeck LLC | $96.24 | 2019-2020 | |
| Abbvie INC. | $92.80 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.40 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $72.50 | 2019-2021 | |
| Tris Pharma INC | $50.88 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.61 | 2020 | |
| Supernus Pharmaceuticals, INC. | $36.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.99 | 2019-2020 | |
| Axsome Therapeutics, INC. | $23.47 | 2024 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Shire North American Group INC | $15.00 | 2019 | |
| Neurocrine Biosciences, INC. | $14.21 | 2020 | |
| Adlon Therapeutics L.P. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.